臨床研究證據顯示，statins 對於糖尿病、高血壓、慢性腎臟疾病及器官移植等冠心病高風險族群，能提供重大的益處。但這些病患常需要多重的藥物治療，因此在受益同時，亦有可能反過來成為交互作用受害的高風險族群。另一方面，基於低密度膽固醇治療目標值不斷地向下修正的結果，為達到理想控制目標，無可避免地將使statins 的治療劑量往上增加。而藥物交互作用與高治療劑量，正是文獻報導statins 引起肌肉病變最常見的原因，也是本案例報導所要探討的兩個重點。在此，我們提出一例因同時併用simvastatin、rosuvastatin 及diltiazem而導致橫紋肌溶解與急性腎衰竭的案例，意在提醒所有臨床醫療人員對於statin 用藥安全的注意。

Clinical trials show that statins are of great benefits to patients with high risk coronary heart diseases (CHD): such as diabetes, hypertension, chronic kidney disease and those receiving transplantation. However,patients who benefit from statin therapy could easily suffer from the interaction of multiple medications simultaneously. On the other hand, the continuous downward revisions of appropriate low-density lipoprotein (LDL) levels will unavoidably result in statin-dose escalation. According to literatures, the main culprits of statin-induced myopathy are drug-drug interaction and high dosage which were evaluated in this report. We also presented another case regarding the rhabdomyolysis and acute renal failure caused by combined therapy of simvastatin, rosuvastatin, and diltiazem to remind clinicians to pay attention to the potential risk of drugdrug interaction when performing the long-term statin therapy to patients with high risk of coronary heart disease.